PT. NOVARTIS INDONESIA

What PT. NOVARTIS INDONESIA does

PT. Novartis Indonesia is the Indonesian operating subsidiary of Novartis AG, a global pharmaceutical company headquartered in Basel, Switzerland (NYSE: NVS). The local entity traces its presence back more than 50 years through predecessor companies Ciba and Sandoz, which were merged in 1996 to form the unified Novartis brand. Operating from Jakarta with approximately 96 employees, the subsidiary markets prescription pharmaceutical products across four major therapeutic areas: cardiovascular, oncology, immunology, and neuroscience.

The product ecosystem centers on prescription medicines, augmented by patient and caregiver support services, healthcare-professional collaboration resources, and the proprietary Medhub Indonesia digital portal — a dedicated platform providing medical information, clinical resources, and access to medical representatives. Distribution occurs through direct partnerships with hospitals and clinics, licensed retail and hospital pharmacy networks, and institutional relationships across the country. The company also operates ESG programs covering ethics, environmental sustainability, global health, and corporate responsibility as part of its positioning.

Revenue is generated through the sale of prescription pharmaceutical products, with pricing negotiated through Indonesian healthcare systems, insurance providers, and government healthcare programs rather than publicly disclosed. The enterprise field-sales motion targets healthcare professionals and medical institutions, leveraging Novartis AG's global R&D pipeline, regulatory dossiers, and brand equity — built over 766 million lives touched globally — to compete in the Indonesian prescription pharmaceutical market. As part of Novartis AG's broader Asia-Pacific portfolio, the entity benefits from parent-level scale while operating as a focused sales-and-marketing affiliate locally.

Name

PT. NOVARTIS INDONESIA

Legal name

Novartis Indonesia

Website

https://id.novartis.com

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

51–100 employees

Short description

PT. Novartis Indonesia is the Indonesian prescription-pharmaceutical subsidiary of Novartis AG, marketing innovative medicines across cardiovascular, oncology, immunology, and neuroscience therapeutic areas. It serves Indonesian patients, caregivers, and healthcare professionals through a 96-employee field-sales operation in Jakarta.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Prescription pharmaceuticals
• Cardiovascular medicines
• Oncology treatments
• Immunology therapies
• Neuroscience pharmaceuticals

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations

Revenue model

1. Prescription Pharmaceutical Products: Novartis Indonesia generates revenue through the sale of prescription medicines, including innovative medicines and generic pharmaceuticals. The company has served Indonesian patients for over 50 years through its predecessor companies Ciba and Sandoz, offering treatments across multiple therapeutic areas including cardiovascular, oncology, immunology, and neuroscience.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

PT. NOVARTIS INDONESIA sells prescription pharmaceutical products across cardiovascular, oncology, immunology, and neuroscience therapeutic areas to healthcare professionals and institutions in Indonesia. The company complements its medicines portfolio with patient and caregiver support services, the Medhub Indonesia portal for healthcare professionals, and ESG programs. Operations have spanned more than 50 years through predecessor companies Ciba and Sandoz, with Indonesia operations consolidated under the Novartis brand following the 1996 merger.

Product overview

PT. NOVARTIS INDONESIA is a pharmaceutical company that has been serving Indonesian patients for more than 50 years through its predecessor companies Ciba and Sandoz. The company operates a portfolio of patient-focused services including patient and caregiver support programs, healthcare professional collaboration platforms, and Medhub Indonesia (a dedicated healthcare professional portal). The company's offerings are complemented by comprehensive ESG programs covering ethics, environmental sustainability, global health, and corporate responsibility. Novartis Indonesia's product ecosystem centers on improving and extending patient lives through collaborative partnerships with the patient community and healthcare professionals.

Differentiator

Problem solved

Functional benefit

Products and services

• Patient and Caregiver Services Support and resource programs for patients and their caregivers navigating treatment journeys, designed to improve and extend people's lives through access to innovative medicines developed by Novartis.
• Healthcare Professional Collaboration Services Resources and engagement services for healthcare professionals in Indonesia, including access to medical information, product details, treatment guidelines, and collaboration on unmet medical needs.
• Medhub Indonesia Dedicated digital portal for healthcare professionals in Indonesia to access medical information, product details, clinical resources, professional development tools, and medical representative contacts.
• ESG Programs Environmental, Social, and Governance programs covering ethics, environmental sustainability, global health, and corporate responsibility initiatives led by Novartis Indonesia as part of its core business objectives.

Quantifiable outcome

• 766 million lives touched by products

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Medhub IndonesiacoreTechnology or IntegrationMedhub Indonesia is a digital platform operated by Novartis Indonesia to serve healthcare professionals with access to medical information, product details, clinical resources, and medical representative contacts. This platform enables direct engagement with the healthcare professional community in Indonesia.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• PT. Pfizer Indonesia: Pfizer's Indonesia subsidiary operates as a multinational pharmaceutical company selling branded prescription medicines across multiple therapeutic areas, directly comparable to Novartis Indonesia's specialty and primary care portfolio.
• PT. Bayer Indonesia: Bayer Indonesia operates a pharmaceutical subsidiary in Indonesia with prescription medicines across specialty care, including cardiovascular, overlapping with Novartis Indonesia's therapeutic portfolio.
• PT. Roche Indonesia: Roche Indonesia is a multinational pharmaceutical subsidiary focused heavily on oncology and specialty therapeutics, directly overlapping with Novartis Indonesia's oncology and specialty immunology offerings.
• PT. Boehringer Ingelheim Indonesia: Boehringer Ingelheim Indonesia is a multinational pharmaceutical subsidiary with specialty prescription medicines, particularly in cardiovascular and respiratory, comparable to Novartis Indonesia's specialty pharma focus.
• PT. Merck Sharp Dohme Indonesia (MSD): MSD Indonesia is a multinational pharmaceutical subsidiary with strong oncology, vaccines, and specialty portfolios, directly comparable to Novartis Indonesia's branded innovative prescription portfolio.
• PT. GSK Indonesia: GSK Indonesia operates as a multinational pharmaceutical subsidiary selling prescription medicines and vaccines in Indonesia, with overlapping specialty and primary care offerings comparable to Novartis Indonesia.
• PT. Sanofi Indonesia: Sanofi Indonesia is a multinational pharmaceutical subsidiary operating in specialty and primary care, with comparable GTM through healthcare professional engagement and prescription medicines distribution.
• PT. Eli Lilly Indonesia: Eli Lilly Indonesia operates as a multinational pharmaceutical subsidiary with specialty prescription medicines in oncology, diabetes, and neuroscience, directly comparable to Novartis Indonesia's therapeutic breadth.
• PT. AstraZeneca Indonesia: AstraZeneca Indonesia is a multinational pharmaceutical subsidiary with strong oncology and cardiovascular portfolios, directly competing with Novartis Indonesia in key therapeutic areas in the country.

Broad incumbents

• PT. Johnson & Johnson Indonesia: Johnson & Johnson Indonesia operates a diversified pharmaceutical and consumer health business in Indonesia, providing broader portfolio overlap with Novartis Indonesia's pharmaceutical operations from a multinational perspective.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pt.-novartis-indonesia

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PT. NOVARTIS INDONESIA